Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye

Kaevalin Lekhanont, Choul Yong Park, Juan Castro Combs, Olan Suwan-Apichon, Ram Rangsin, Roy S. Chuck

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: The aim of this study was to compare the effect of topical olopatadine, epinastine, and lubricant eye drops on dry eye ocular surface disease in the botulinum toxin B (BTX-B)-induced mouse model of keratoconjunctivitis sicca. Methods: CBA/J mice were randomized into 3 experimental groups of 10 animals each. All mice received a transconjunctival injection of 0.05 mL of 20-mU BTX-B solutions into the left lacrimal gland. Three (3) days after intralacrimal gland injections, each group received treatment with twice-daily topical lubricant as a control, 0.1% olopatadine, or 0.05% epinastine eye drops. To monitor the progression of dry eye tear production, an ocular surface fluorescein staining score was evaluated in each of the 3 experimental groups. Results: Three (3) days after the intralacrimal gland injection of BTX-B, aqueous tear production was significantly decreased (1.95 ± 0.64 mm), compared to baseline level (2.69 ± 0.66 mm; P < 0.001). Similarly, there was a statistically significant increase in the proportion of mice with a corneal staining score of 2 or greater at 3 days postinjection, compared to the preinjection value (P < 0.001). There were no statistically significant differences in aqueous tear production between the 3 different medication groups at all time points. Aqueous tear production in neither the olopatadine nor the epinastine-challenged groups was further decreased compared to the lubricant-treated group. Difference in the proportion of mice with a low- and high corneal staining score between the control and study groups did not reach statistical significance throughout the 4-week experimental period. In addition, changes in corneal fluorescein staining of the olopatadine group versus the epinastine group did not show a statistically significant difference. Conclusions: Topical olopatadine and epinastine do not cause significantly additional damage to the compromised ocular surface secondary to dry eye after continuous 4-week, twice-daily application. Topical olopatadine and epinastine appear to have comparable effects on aqueous tear-production and corneal-surface changes in this mouse model.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume23
Issue number1
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Tears
Staining and Labeling
Lubricants
Fluorescein
Injections
Keratoconjunctivitis Sicca
Lacrimal Apparatus
Inbred CBA Mouse
Eye Diseases
Ophthalmic Solutions
Olopatadine Hydrochloride
rimabotulinumtoxinB
epinastine
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. / Lekhanont, Kaevalin; Park, Choul Yong; Combs, Juan Castro; Suwan-Apichon, Olan; Rangsin, Ram; Chuck, Roy S.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 23, No. 1, 02.2007, p. 83-88.

Research output: Contribution to journalArticle

Lekhanont, Kaevalin ; Park, Choul Yong ; Combs, Juan Castro ; Suwan-Apichon, Olan ; Rangsin, Ram ; Chuck, Roy S. / Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. In: Journal of Ocular Pharmacology and Therapeutics. 2007 ; Vol. 23, No. 1. pp. 83-88.
@article{4cfb9ba27bc24d60983fc07820ff9065,
title = "Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye",
abstract = "Purpose: The aim of this study was to compare the effect of topical olopatadine, epinastine, and lubricant eye drops on dry eye ocular surface disease in the botulinum toxin B (BTX-B)-induced mouse model of keratoconjunctivitis sicca. Methods: CBA/J mice were randomized into 3 experimental groups of 10 animals each. All mice received a transconjunctival injection of 0.05 mL of 20-mU BTX-B solutions into the left lacrimal gland. Three (3) days after intralacrimal gland injections, each group received treatment with twice-daily topical lubricant as a control, 0.1{\%} olopatadine, or 0.05{\%} epinastine eye drops. To monitor the progression of dry eye tear production, an ocular surface fluorescein staining score was evaluated in each of the 3 experimental groups. Results: Three (3) days after the intralacrimal gland injection of BTX-B, aqueous tear production was significantly decreased (1.95 ± 0.64 mm), compared to baseline level (2.69 ± 0.66 mm; P < 0.001). Similarly, there was a statistically significant increase in the proportion of mice with a corneal staining score of 2 or greater at 3 days postinjection, compared to the preinjection value (P < 0.001). There were no statistically significant differences in aqueous tear production between the 3 different medication groups at all time points. Aqueous tear production in neither the olopatadine nor the epinastine-challenged groups was further decreased compared to the lubricant-treated group. Difference in the proportion of mice with a low- and high corneal staining score between the control and study groups did not reach statistical significance throughout the 4-week experimental period. In addition, changes in corneal fluorescein staining of the olopatadine group versus the epinastine group did not show a statistically significant difference. Conclusions: Topical olopatadine and epinastine do not cause significantly additional damage to the compromised ocular surface secondary to dry eye after continuous 4-week, twice-daily application. Topical olopatadine and epinastine appear to have comparable effects on aqueous tear-production and corneal-surface changes in this mouse model.",
author = "Kaevalin Lekhanont and Park, {Choul Yong} and Combs, {Juan Castro} and Olan Suwan-Apichon and Ram Rangsin and Chuck, {Roy S.}",
year = "2007",
month = "2",
doi = "10.1089/jop.2006.0097",
language = "English (US)",
volume = "23",
pages = "83--88",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye

AU - Lekhanont, Kaevalin

AU - Park, Choul Yong

AU - Combs, Juan Castro

AU - Suwan-Apichon, Olan

AU - Rangsin, Ram

AU - Chuck, Roy S.

PY - 2007/2

Y1 - 2007/2

N2 - Purpose: The aim of this study was to compare the effect of topical olopatadine, epinastine, and lubricant eye drops on dry eye ocular surface disease in the botulinum toxin B (BTX-B)-induced mouse model of keratoconjunctivitis sicca. Methods: CBA/J mice were randomized into 3 experimental groups of 10 animals each. All mice received a transconjunctival injection of 0.05 mL of 20-mU BTX-B solutions into the left lacrimal gland. Three (3) days after intralacrimal gland injections, each group received treatment with twice-daily topical lubricant as a control, 0.1% olopatadine, or 0.05% epinastine eye drops. To monitor the progression of dry eye tear production, an ocular surface fluorescein staining score was evaluated in each of the 3 experimental groups. Results: Three (3) days after the intralacrimal gland injection of BTX-B, aqueous tear production was significantly decreased (1.95 ± 0.64 mm), compared to baseline level (2.69 ± 0.66 mm; P < 0.001). Similarly, there was a statistically significant increase in the proportion of mice with a corneal staining score of 2 or greater at 3 days postinjection, compared to the preinjection value (P < 0.001). There were no statistically significant differences in aqueous tear production between the 3 different medication groups at all time points. Aqueous tear production in neither the olopatadine nor the epinastine-challenged groups was further decreased compared to the lubricant-treated group. Difference in the proportion of mice with a low- and high corneal staining score between the control and study groups did not reach statistical significance throughout the 4-week experimental period. In addition, changes in corneal fluorescein staining of the olopatadine group versus the epinastine group did not show a statistically significant difference. Conclusions: Topical olopatadine and epinastine do not cause significantly additional damage to the compromised ocular surface secondary to dry eye after continuous 4-week, twice-daily application. Topical olopatadine and epinastine appear to have comparable effects on aqueous tear-production and corneal-surface changes in this mouse model.

AB - Purpose: The aim of this study was to compare the effect of topical olopatadine, epinastine, and lubricant eye drops on dry eye ocular surface disease in the botulinum toxin B (BTX-B)-induced mouse model of keratoconjunctivitis sicca. Methods: CBA/J mice were randomized into 3 experimental groups of 10 animals each. All mice received a transconjunctival injection of 0.05 mL of 20-mU BTX-B solutions into the left lacrimal gland. Three (3) days after intralacrimal gland injections, each group received treatment with twice-daily topical lubricant as a control, 0.1% olopatadine, or 0.05% epinastine eye drops. To monitor the progression of dry eye tear production, an ocular surface fluorescein staining score was evaluated in each of the 3 experimental groups. Results: Three (3) days after the intralacrimal gland injection of BTX-B, aqueous tear production was significantly decreased (1.95 ± 0.64 mm), compared to baseline level (2.69 ± 0.66 mm; P < 0.001). Similarly, there was a statistically significant increase in the proportion of mice with a corneal staining score of 2 or greater at 3 days postinjection, compared to the preinjection value (P < 0.001). There were no statistically significant differences in aqueous tear production between the 3 different medication groups at all time points. Aqueous tear production in neither the olopatadine nor the epinastine-challenged groups was further decreased compared to the lubricant-treated group. Difference in the proportion of mice with a low- and high corneal staining score between the control and study groups did not reach statistical significance throughout the 4-week experimental period. In addition, changes in corneal fluorescein staining of the olopatadine group versus the epinastine group did not show a statistically significant difference. Conclusions: Topical olopatadine and epinastine do not cause significantly additional damage to the compromised ocular surface secondary to dry eye after continuous 4-week, twice-daily application. Topical olopatadine and epinastine appear to have comparable effects on aqueous tear-production and corneal-surface changes in this mouse model.

UR - http://www.scopus.com/inward/record.url?scp=33947374686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947374686&partnerID=8YFLogxK

U2 - 10.1089/jop.2006.0097

DO - 10.1089/jop.2006.0097

M3 - Article

VL - 23

SP - 83

EP - 88

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -